FATE - Fate Therapeutics, Inc.
| Previous Close | 16.14 |
| Open | 16.09 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1200 |
| Day's Range | 15.60 - 16.51 |
| 52 Week Range | 8.35 - 19.11 |
| Volume | 527,935 |
| Avg. Volume | 708,066 |
| Market Cap | 1.037B |
| Beta (3Y Monthly) | 2.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.18 |
| Earnings Date | Mar 4, 2019 - Mar 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.17 |
- GlobeNewswire•8 days ago
Fate Therapeutics Announces the Appointment of Karin Jooss, Ph.D. to its Board of Directors
Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Karin Jooss, Ph.D. has been appointed to the Company’s Board of Directors. Dr. Jooss has more than 20 years of experience in oncology and immunology research and development, and is currently the Executive Vice President of Research and Chief Scientific Officer of Gritstone Oncology, Inc., a clinical-stage biotechnology company developing next-generation cancer immunotherapies targeting tumor-specific neoantigens.
- Thomson Reuters StreetEvents•14 days ago
Edited Transcript of FATE earnings conference call or presentation 5-Mar-19 10:00pm GMT
Q4 2018 Fate Therapeutics Inc Earnings Call
Motley Fool•20 days agoFate Therapeutics Inc (FATE) Q4 2018 Earnings Conference Call Transcript
FATE earnings call for the period ending December 31, 2018.
- GlobeNewswire•20 days ago
Fate Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress
First Patient Treated with FT500 Off-the-Shelf NK Cell Cancer Immunotherapy in Landmark Clinical Trial Marks First-ever Human Administration of iPSC-derived Cell Therapy in.
- ACCESSWIRE•20 days ago
Fate Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 5, 2019 / Fate Therapeutics, Inc. (NASDAQ: FATE) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 5, 2019 at 5:00 PM ...
- GlobeNewswire•25 days ago
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2018 Financial Results
SAN DIEGO, Feb. 28, 2019 -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular.
- Zacks•26 days ago
Cronos (CRON) to Report Q4 Earnings: What's in the Cards?
Investors will focus on regular top and bottom-line numbers along with pipeline progress when Cronos (CRON) reports fourth-quarter results.
- Zacks•29 days ago
Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Fate Therapeutics (FATE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•29 days ago
Market Trends Toward New Normal in Nuance Communications, Fate Therapeutics, Hamilton Lane, InflaRx N.V, Enerplus, and ManTech International — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Feb. 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•last month
Fate Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference
SAN DIEGO, Feb. 22, 2019 -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular.
- GlobeNewswire•last month
Fate Therapeutics Appoints Sarah Cooley, M.D., M.S. as Senior Vice President, Clinical Translation
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Sarah Cooley, M.D., M.S., a leading expert in the field of natural killer (NK) cell receptor immunogenetics and in the clinical development of NK cell cancer immunotherapies, has joined the Company as Senior Vice President, Clinical Translation. Dr. Cooley brings to Fate Therapeutics more than 12 years of leadership in the field of NK cell clinical research and development, having most recently served as Associate Professor of Medicine in the Division of Hematology, Oncology and Transplantation at the University of Minnesota.
- GlobeNewswire•2 months ago
Fate Therapeutics to Present at Guggenheim Healthcare Talks Idea Forum Oncology Day
SAN DIEGO, Feb. 07, 2019 -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular.
- MarketWatch•2 months ago
Fate Therapeutics stock up 11% after FDA clears IND application
Shares of Fate Therapeutics Inc. were up 11% in premarket trade Wednesday after the company announced that the FDA had cleared its investigational new drug application for FT516, a potential therapy for patients with certain blood cancers. FT516 is a natural killer cell product engineered to make a surface protein called the CD16 Fc receptor. CD16 is a surface receptor that helps regulate an immune response where natural killer cells bind to and kill cancer cells. Cancer patients can have reduced CD16, inhibiting their bodies' tumor-killing responses. FT516's CD16 Fc receptor has been modified so that it will not have this problem -- the idea is that administering this therapy will allow for a better anti-tumor response in cancer patients. Fate Therapeutics said its initial study of FT516 will assess the safety and tolerability of three weekly doses of the therapy to treat certain later-stage blood cancers. Shares of Fate Therapeutics have gained 8% in the year to date, while the S&P 500 has gained 9.2%.
- GlobeNewswire•2 months ago
Fate Therapeutics Announces FDA Clearance of IND Application for World’s First Cell Therapy Derived from an Engineered Pluripotent Stem Cell
Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for FT516, the Company’s off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered to express a novel CD16 Fc receptor. FT516 is the first-ever cell therapy derived from a genetically engineered pluripotent stem cell cleared for clinical testing in the world, and is the Company’s second off-the-shelf, iPSC-derived NK cell product candidate cleared for clinical investigation by the FDA within the past two months.
- Simply Wall St.•2 months ago
Why Fate Therapeutics, Inc.’s (NASDAQ:FATE) CEO Pay Matters To You
J. Wolchko became the CEO of Fate Therapeutics, Inc. (NASDAQ:FATE) in 2015. First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider Read More...
Market Realist•3 months agoVanda Pharmaceuticals: Recent Developments and Analyst Ratings
On December 21, Vanda Pharmaceuticals (VNDA) stock closed at $24.00, which is a ~1.64% decline from its prior close of $24.40 on December 20, 2018. Vanda Pharmaceuticals stock price grew from $15.20 at the close of market on December 29, 2017, to $24.00 on December 21, 2018, reflecting ~58% YTD growth.
- Insider Monkey•3 months ago
Fate Therapeutics Inc (FATE) Hedge Funds Are Snapping Up
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]
- GlobeNewswire•4 months ago
Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting
Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced new preclinical data on the Company’s induced pluripotent stem cell (iPSC) product platform and its iPSC-derived, off-the-shelf cell-based cancer immunotherapy pipeline at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition. Last week, the Company announced that the U.S. Food and Drug Administration (FDA) allowed its Investigational New Drug (IND) Application for FT500, the Company’s universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master iPSC line.
- GlobeNewswire•4 months ago
Fate Therapeutics Secures Exclusive Option to Novel Humanized anti-BCMA CAR Constructs for Development of iPSC-derived Cell Products
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it has secured an exclusive option to an intellectual property portfolio owned by the Max Delbrück Center for Molecular Medicine (MDC) covering novel humanized chimeric antigen receptor (CAR) constructs that uniquely and specifically bind B-cell Maturation Antigen (BCMA). Under the agreement with MDC, Fate Therapeutics holds an exclusive option to exclusively license the portfolio for all cell products, including CAR NK- and T-cell products, derived from induced pluripotent stem cells (iPSCs).
- Zacks•4 months ago
Fate Therapeutics (FATE) Jumps: Stock Rises 8.9%
Fate Therapeutics (FATE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
- GlobeNewswire•4 months ago
Investor Expectations to Drive Momentum within Virtu Financial, Fate Therapeutics, Tandem Diabetes Care, Eli Lilly, Griffon, and Coherus BioSciences — Discovering Underlying Factors of Influence
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- ACCESSWIRE•4 months ago
How Healthcare Is Evolving & Sector Stocks To Watch
CORAL GABLES, FL / ACCESSWIRE / November 30,2018 / The Global Connected Healthcare Market was valued at USD $1,860.26 million in2017, and is expected to grow at a CAGR of 28.3% by 2025. There has been a growing increase in the use of smartphones by physicians leading to a practice of digital health. The global digital health market is expanding at a fast pace.
- GlobeNewswire•4 months ago
Fate Therapeutics Announces FDA Clearance of Landmark IND for FT500 iPSC-derived, Off-the-Shelf NK Cell Cancer Immunotherapy
Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) Application for FT500, the Company’s universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line. The clinical trial of FT500 is expected to be the first-ever clinical investigation in the U.S. of an iPSC-derived cell product.
- Investor's Business Daily•4 months ago
3 Themes To Watch As Biopharmas 'Bring Some Excitement' In Blood Cancer
The American Society of Hematology meeting could "bring some excitement" this weekend in San Diego as biopharma giants take their blood cancer treatments to bat.
